
Galen Robotics Receives First FDA Approval for Robotic ENT Surgical Robot; Announces Series B Funding Round
Galen Robotics, Inc., a developer of innovative robotically assisted surgical systems, has recently announced U.S. Food and Drug Administration (FDA) granting De Novo status to its Galen ES cooperatively controlled robotic surgical assistant in ear nose and throat surgery.
Galen Robotics is at the forefront of Digital-Surgery-as-a-Service (DSaaS). The company offers the world’s first cooperatively powered robotic surgical assistant platform designed for Ear, Nose, and Throat (ENT) surgery. The device is a cooperative powered surgical assistance which operates collaboratively with the surgeon’s actions, enabling accurate and precise, stable positioning of surgical instruments while preserving the surgeon’s direct physical control over them.
Following the FDA approval, Galen Robotics announced the commencement of a bridge round as part of its Series B financing. Bruce W Lichorowic, CEO of Galen Robotics, expressed his enthusiasm for this significant development, stating, “This bridge round marks the advent of an exciting phase in our journey. The additional funding will play a pivotal role in boosting our operating capabilities and manufacturing domain. The impressive reception we received from our Galen ES De Dovo further bolsters our commitment to continue pushing the boundaries, leading to improved patient care and surgical outcomes.”